Xeris Biopharma Holdings Inc (NASDAQ: XERS) stock jumped 2.82% on Monday to $1.82 against a previous-day closing price of $1.77. With 1.88 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.08 million shares. The 52-week range on XERS shows that it touched its highest point at $3.07 and its lowest point at $0.97 during that stretch. It currently has a 1-year price target of $4.60. Beta for the stock currently stands at 1.43.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of XERS was up-trending over the past week, with a rise of 12.35%, but this was up by 4.60% over a month. Three-month performance dropped to -20.52% while six-month performance fell -38.31%. The stock gained 43.31% in the past year, while it has gained 36.84% so far this year. A look at the trailing 12-month EPS for XERS yields -0.45 with Next year EPS estimates of -0.25. For the next quarter, that number is -0.09. This implies an EPS growth rate of 44.00% for this year and 37.34% for next year.
Float and Shares Shorts:
At present, 136.27 million XERS shares are outstanding with a float of 129.56 million shares on hand for trading. On Oct 30, 2023, short shares totaled 7.79 million, which was 5.65% higher than short shares on Sep 28, 2023. In addition to Mr. Paul R. Edick as the firm’s Chairman & CEO, Mr. John P. Shannon serves as its President & COO.
Institutional Ownership:
Through their ownership of 38.29% of XERS’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 4.54% of XERS, in contrast to 22.09% held by mutual funds. Shares owned by individuals account for 17.22%. As the largest shareholder in XERS with 6.09% of the stake, BlackRock Fund Advisors holds 8,401,872 shares worth 8,401,872. A second-largest stockholder of XERS, The Vanguard Group, Inc., holds 6,759,197 shares, controlling over 4.90% of the firm’s shares. Stonepine Capital Management LLC is the third largest shareholder in XERS, holding 5,915,372 shares or 4.28% stake. With a 2.98% stake in XERS, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 4,106,991 shares are owned by the mutual fund manager. The iShares Russell 2000 ETF, which owns about 2.24% of XERS stock, is the second-largest Mutual Fund holder. It holds 3,093,962 shares valued at 5.66 million. Xtrackers SICAV – S&P Global Infr holds 1.45% of the stake in XERS, owning 1,999,189 shares worth 3.66 million.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for XERS since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With XERS analysts setting a high price target of $5.50 and a low target of $4.00, the average target price over the next 12 months is $4.60. Based on these targets, XERS could surge 202.2% to reach the target high and rise by 119.78% to reach the target low. Reaching the average price target will result in a growth of 152.75% from current levels.
Summary of Insider Activity:
Insiders traded XERS stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 16 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 3,262,500 while 0 shares were sold.
